Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders

Not Applicable

Completed

• Conditions: Myelodysplastic Syndromes; Myeloproliferative Disorders; Blood and Marrow Transplant (BMT); Myelodysplastic Syndromes (MDS); Myeloproliferative Disorders (MPD)

• Registration Number: NCT00186576
• Lead Sponsor: Stanford University

Brief Summary

To improve survival outcomes for patients with MDS and MPD with a nonmyeloablative allogeneic hematopoietic cell transplant.

Detailed Description

Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)

Study Timeline

• Study Start: 2001-12
• Primary Completion: 2004-03
• Study First Submitted: 2005-09-14
• Study First Submitted QC: 2005-09-14
• Study First Posted: 2005-09-16
• Study Completion: 2010-07
• Status Verified: 2010-10
• Last Update Submitted: 2010-10-13
• Last Update Posted: 2010-10-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Myelodysplastic Syndromes

• Myeloproliferative Disorders
• HLA matched donor available

Exclusion Criteria

• organ dysfunction

• HIV positive

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Efficacy of transplant	1 year

Secondary Outcome Measures

Name	Time	Method
safety profile of nonmyeloablative transplant, graft versus host disease, graft rejection, non-relapse mortality, use of donor lymphocyte infusion	1 year

Trial Locations

Locations (1)

Stanford University School of Medicine; 🇺🇸 Stanford, California, United States